07:00:43 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018


Polarcool är verksamma inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2022-06-30 10:01:00

PolarCool AB (publ) has entered into a commercial agreement with HV71 for an additional PolarCap® System, allowing HV71 to now offer 2 PolarCap® Systems to their players. The agreement is a supplementary agreement to the league agreement that PolarCool have with the Swedish Hockey League.

PolarCool develops and markets the product PolarCap® which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby and handball. PolarCool has recently landed most of its strategic agreements with several major European clubs yet aims to continue to broaden its presence in both higher and lower divisions in the Swedish domestic market.

Prior to the 2021-2022 season, the agreement with SHL was extended, which means that the PolarCap® System is available during all SHL games, aiming to reduce the negative effects of concussions. HV71 will now be the first club to sign an supplementary agreement for an additional PolarCap®.

HV71's physiotherapist Andreas Frostemark comments:

- It feels good that we will have another PolarCap® System available for our organisation. Since we have had the system for almost five years, we have been able to evaluate the product first-hand. We in the medical team as well as the players are positive about the treatment method. We see the use of the PolarCap® System as a given part in our management to reduce the effects of concussions.

PolarCool's CEO Erik Andersson comments:

- HV71 have been at the forefront of our project from the start, and thus have extensive experience using PolarCap®. Having partners extending and signing supplementary agreements is the best confirmation of customer satisfaction. We now look forward to continued cooperation towards our common goal of alleviating the effects of head injuries on players suffering concussions.